secwatch / observer
8-K filed April 17, 2023, 7:59 PM ET ticker NKTR CIK 0000906709
other material confidence high sentiment negative materiality 0.80

NEKTAR THERAPEUTICS (NKTR): restructuring charge — Nektar cuts SF workforce 60%, extends cash runway to mid-2026; CFO departs

NEKTAR THERAPEUTICS

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Sandra Gardiner

interim Chief Financial Officer
NKTR · NEKTAR THERAPEUTICS
Effective
2023-04-17
Filed
April 17, 2023, 7:59 PM ET
Effective April 17, 2023, Sandra Gardiner, a partner in FLG Partners, LLC, a Silicon Valley chief financial officer services and board advisory firm (“FLG”), will be retained as the interim Chief Financial Officer and shall be the principal financial and accounting officer of the Company.
Departed

Jillian Thomsen

Chief Financial Officer
NKTR · NEKTAR THERAPEUTICS
Effective
2023-04-17
Successor
Sandra Gardiner
Filed
April 17, 2023, 7:59 PM ET
On April 17, 2023, Jillian Thomsen stepped down as the Chief Financial Officer of the Company and will depart the Company in June 2023 following a transition period.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Sandra Gardiner was appointed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.

Action
retained as
Role
interim Chief Financial Officer
Exact text from the filing
Effective April 17, 2023, Sandra Gardiner, a partner in FLG Partners, LLC, a Silicon Valley chief financial officer services and board advisory firm (“FLG”), will be retained as the interim Chief Financial Officer and shall be the principal financial and accounting officer of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Jillian Thomsen departed as Chief Financial Officer at NEKTAR THERAPEUTICS.

Action
stepped down
Role
Chief Financial Officer
Exact text from the filing
On April 17, 2023, Jillian Thomsen stepped down as the Chief Financial Officer of the Company and will depart the Company in June 2023 following a transition period.
View on SEC.gov
Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

NEKTAR THERAPEUTICS announced a restructuring with charges of non-recurring cash payments of approximately $8 million affecting San Francisco-based workforce (approximately 60%).

Type
restructuring
Charge
non-recurring cash payments of approximately $8 million
Affected area
San Francisco-based workforce
Headcount
approximately 60%
Exact text from the filing
On April 17, 2023, the duly authorized officers of the “Company approved a new strategic reprioritization and cost restructuring plan (the “2023 Restructuring Plan”). Pursuant to the 2023 Restructuring Plan, the Company will undertake several cost-reduction actions to reduce costs, including a reduction in its San Francisco-based workforce by approximately 60% that is expected to be substantially completed by June 2023. In connection with these actions, the Company expects non-recurring cash payments of approximately $8 million primarily in the second quarter of 2023 associated principally with the workforce reduction, including one-time employee severance and termination payments.
View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR
accession 0001213900-23-030323
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.